Akcea discloses new thrombocytopenia case for volanesorsen

Akcea Therapeutics Inc. (NASDAQ:AKCA) disclosed an additional case of grade 4 thrombocytopenia in an open-label extension of its volanesorsen (IONIS-APOCIIIRx) to treat familial chylomicronemia syndrome (FCS), a rare lipid

Read the full 290 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE